Celcuity (CELC) Tops Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Celcuity Reports First Quarter 2019 Financial Results
May 7, 2019 4:01 PM EDTMINNEAPOLIS--(BUSINESS WIRE)-- Celcuity Inc. (Nasdaq: CELC), a functional cellular analysis company that is discovering new cancer subtypes and commercializing diagnostic tests designed to significantly improve clinical outcomes of cancer patients treated with targeted therapies, announced financial results for the first quarter ended March 31, 2019.
Unless otherwise stated, all comparisons are for the first quarter ended March 31, 2019, compared to the first quarter ended March 31, 2018.
Celcuity reported a net loss of $1.85 million, or $0.18 per share, for the first quarter of 2019, compared to a net loss of $1.97 million, or $0.19 per share, for the first quarter of... More



